Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions

NCT04189588 is registered in ClinicalTrials.gov with TerSera Therapeutics LLC as lead sponsor.

NCT NCT04189588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions
Lead sponsor
TerSera Therapeutics LLC
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2020
Completion date
December 23, 2020
Enrollment
34 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

oncology patients receiving chemotherapy